FY2010 - Oak Ridge National Laboratory
FY2010 - Oak Ridge National Laboratory
FY2010 - Oak Ridge National Laboratory
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Director’s R&D Fund—<br />
Ultrascale Computing and Data Science<br />
05282<br />
High-Throughput Computational Screening Approach<br />
for Systems Medicine<br />
Pratul K. Agarwal<br />
Project Description<br />
High-performance computing continues to revolutionize biology. Computational thinking and techniques<br />
will have a significant impact on the future biological research as it is substantially reducing the time<br />
between data acquisition and knowledge discovery. Human health, in particular, is poised to benefit<br />
considerably from the impact of computational modeling and simulations. The search for new medicines<br />
is based on the identification of potential drug candidates that bind to and change the activity of disease<br />
targets (proteins). Traditionally this search has centered upon the active site of an enzyme or binding site<br />
of a receptor. Recently, we have demonstrated that protein sites on the surface (allosteric sites) are<br />
capable of altering protein activity in much the same way as traditional drug agents in the buried active<br />
site. However, due to the size of the energy space of the protein as well as the chemical space of the<br />
compounds, screening presents a challenging problem.<br />
Here, we propose a joint effort between the computational and structural biologists and medicinal and<br />
computational drug design chemists to develop new high-throughput methods for approaching rational<br />
drug design and drug discovery. High-performance computing will be used to predict the location of<br />
allosteric sites in protein targets and to simulate the interaction between drug-like small molecules and<br />
target sites. In silico–based screening of drug candidates will lead to a considerable cost and time saving<br />
for the expensive wet-lab screening and therefore accelerate critical steps in systems medicine.<br />
Mission Relevance<br />
Computational biology is an important component of DOE’s Genomic Science (formerly GTL:Genomics)<br />
initiative. The project will allow development of high-performance computing tools and software for<br />
characterization of biomolecular-biomolecular interactions, which is an important components of<br />
Genomic Science Program goals. The fundamental understanding of the biological processes occurring at<br />
the molecular level in the living cell, as enabled by the project, has fundamental implications in energy<br />
and environmental research. The project is relevant to the DOE Office of Biological and Environmental<br />
Research (DOE BER) as well as the Office of Advanced Scientific Computing Research (DOE ASCR).<br />
The proposed research for development of tools and software for systems medicine is relevant to human<br />
health. Therefore, it is relevant to the mission of the <strong>National</strong> Institutes of Health (NIH), in particular to<br />
the <strong>National</strong> Institute of General Medical Sciences (NIGMS). The outcome of the research would lower<br />
time and cost for discovery of new medicine and, therefore, promote human health.<br />
Results and Accomplishments<br />
Our underlying approach for identification of the allosteric sites is based on the characterization of protein<br />
dynamics (or slow conformational fluctuations) in relation to the rate-limiting steps in the catalytic cycle<br />
of enzymes. We have developed and used theoretical modeling and computational simulations that allow<br />
refining of the factors that enable the identification of allosteric sites. Specifically, we have focused on<br />
mapping the protein residues from the active-site to surface regions that are the prospective allosteric<br />
sites.<br />
Using the developed approach, we have successfully identified allosteric sites for two medically<br />
important target enzymes. Enzyme dihydrofolate reductase (DHFR) is an anticancer target, while the<br />
80